Showing 15 posts of 42 posts found.

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

August 18, 2023
Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …


Novo Nordisk’s Wegovy reduces risk of cardiovascular events

August 9, 2023
Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide

Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …


Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain

July 26, 2023
Sales and Marketing Amarin, Cardiology, Spanish Drug Pricing Committee, Vazkepa, cardiovascular

Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain …


First ever human implant of fully artificial heart announced

July 15, 2021

CARMAT has announced that the first ever human implantation of their fully artificial heart, which was designed as a therapeutic …

Phoenix Cardiac gains CE Mark for “game-changer” MR device

April 26, 2021
Sales and Marketing CE Mark, EU, cardiovascular

Phoenix Cardiac Devices have received CE Mark certification for its BACE (basal annuloplasty of the cardia externally) device, a novel …


MHRA gives green light to new cardiovascular treatment

April 23, 2021
Medical Communications MHRA, cardiovascular

The MHRA has granted a Great Britain Marketing Authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce the risk …


Significant lack of women and minorities involved in clinical trials for cardiometabolic medication, research shows

June 1, 2020
Sales and Marketing cardio, cardiovascular, cvd

Women and minorities, particularly African Americans, continue to be under represented in clinical trials for cardiometabolic medication, according to a …


ACC.20 cancelled due to coronavirus fears

March 9, 2020
Manufacturing and Production, Medical Communications cardio, cardiology, cardiovascular

The American College of Cardiology has cancelled its upcoming ACC.20 event with the World Congress of Cardiology due to concerns …

Insider Interview: Reducing the risk of adverse cardiovascular events

February 3, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Insider Interview, cardiovascular, heart disease, pharma

Rodrigo Gribble, Vice President Cardiovascular at AstraZeneca, breaks down recently published data from the PEGASUS trial of ticagrelor, a potential …

Heart disease deaths increase for first time in 50 years

May 13, 2019
Sales and Marketing BHF, UK, cardiovascular, health, heart disease, obesity

Deaths from heart disease among people under the age of 75 have increased for the first time in 50 years. …


Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease

April 16, 2019
Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma

Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …


AZ’s Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows

March 19, 2019
Manufacturing and Production, Research and Development AstraZeneca, cardiovascular, farxiga, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing …


Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk

March 18, 2019
Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent

Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …


FDA approve valsartan generic after shortages of supply

March 13, 2019
Manufacturing and Production, Research and Development FDA, blood pressure drugs, cardiovascular, generic, valsartan

The FDA has approved a new generic version of blood pressure drug valsartan. The approval comes amid shortages in supply …


Novartis’ Entresto tops enalapril in stabilised heart failure patients

November 13, 2018
Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma

Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …

Latest content